CPhI Pharma Awards seek nominations for excellence in biopharma development and manufacturing.
Each day, the editors of BioPharm International receive press releases promoting potential: announcements of new products, services, methods, and processes destined to solve a problem, cure a disease, save money, and-in some cases of extreme hyperbole-change the world.
As natural cynics, the editors question the validity of these projections of great success. We also appreciate the true successes, as recognized by independent evaluations by industry experts. The CPhI Pharma Awards are one such program to recognize excellence in biopharma development and manufacturing.
The awards program recognizes companies and individuals helping to accelerate the development of biopharmaceuticals through the introduction of innovations, new technologies, and strategies that support drug development, manufacturing, and distribution. The program is organized by CPhI Worldwide, a global tradeshow for the pharma industry, scheduled for Oct. 4-6, 2016 in Barcelona, Spain. CPhI and BioPharm International are UBM plc brands.
The 2016 awards are organized into 12 categories including:
Applications for the 2016 CPhI Pharma Awards must be submitted by Aug. 14, 2016 via the awards website at awards.cphi.com. Finalists will be announced in September 2016. The awards will be presented on Oct. 4, 2016 during the Pharma Awards Gala at CPhI Worldwide.
Article DetailsBioPharm International
Vol. 29, No. 7
Page: 6
Citation
When referring to this article, please cite it as R. Peters, " Recognizing Biopharma Industry Excellence," BioPharm International 29 (7) 2016.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.